anagliptin

anagliptin hydrochloride salt is the active compound

Also Known As:

(S)-N-(2-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo(1,5-a)pyrimidine-6-carboxamide; N-(2-((2-((2S)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methyl pyrazolo(1,5-a)pyrimidine-6-carboxamide hydrochloride; anagliptin hydrochloride; Pyrazolo(1,5-a)pyrimidine-6-carboxamide, N-(2-((2-((2S)-2-cyano-1-pyrrolidinyl)-2-oxoethyl)amino)-2-methylpropyl)-2-methyl-

Networked: 61 relevant articles (12 outcomes, 25 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - anagliptin: 61

Experts

1.	Nomiyama, Takashi: 9 articles (01/2022 - 03/2013)
2.	Arasaki, Osamu: 8 articles (01/2022 - 01/2018)
3.	Morimoto, Takeshi: 8 articles (01/2022 - 01/2018)
4.	Node, Koichi: 8 articles (01/2022 - 01/2018)
5.	Shimabukuro, Michio: 8 articles (01/2022 - 01/2018)
6.	Ueda, Shinichiro: 8 articles (01/2022 - 01/2018)
7.	Sakuma, Mio: 7 articles (01/2022 - 11/2019)
8.	Goto, Moritaka: 6 articles (01/2020 - 07/2013)
9.	Yamashita, Satoko: 5 articles (01/2020 - 01/2016)
10.	Terauchi, Yasuo: 4 articles (08/2022 - 01/2015)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2015 - "The aim of this study was to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes in a double-blind randomized placebo-controlled study. " 01/01/2015 - "A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes." 01/01/2023 - "Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial." 01/01/2015 - "Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability." 01/01/2015 - "Therefore, the use of anagliptin in patients with type 2 diabetes is considered to be safe and effective for both monotherapy and combination therapy. "
2.	Body Weight (Weight, Body) 10/01/2013 - "Treatment with anagliptin clearly improved body weight loss and disease activity index in the recovery phase. " 12/01/2017 - "Body weight and food consumption did not alter following treatment with anagliptin. " 07/01/2013 - "After 10weeks of treatment with 0.3% anagliptin, body weight gain and food intake were significantly suppressed in both wild-type and GckKO mice. " 04/01/2022 - "The results revealed that anagliptin effectively reduced tumor growth, but did not affect the body weight of treated mice. " 05/28/2020 - "These data suggested that anagliptin ameliorated leptin resistance induced by HFHSD and thereby decreased food intake and body weight. "
3.	Albuminuria 01/01/2017 - "Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner." 01/01/2017 - "Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner."
4.	Insulin Resistance 10/01/2020 - "DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice." 11/01/2016 - "Anagliptin may be a promising agent to ameliorate skeletal muscle insulin resistance in obese patients with type 2 diabetes." 07/01/2013 - "In addition, 0.3% anagliptin ameliorated insulin resistance and glucose intolerance in both genotypes of mice. " 07/01/2013 - "High-dose anagliptin treatment improved glucose tolerance by suppression of body weight gain and amelioration of insulin resistance, whereas low-dose anagliptin treatment improved glucose tolerance by enhancing insulin secretion." 07/01/2013 - "On the other hand, treatment with 0.05% anagliptin was not associated with any significant change of the body weight, food intake or insulin sensitivity in either genotype of mice, but it did improve the glucose tolerance by enhancing insulin secretion and increasing the β-cell mass in both genotypes of mice. "
5.	Obesity 12/01/2016 - "Add-on therapy with anagliptin for 52 weeks improved glycemic control and increased the area under the curve of biologically active GLP-1 concentration without altering obesity indicators. " 05/28/2020 - "Anagliptin suppresses diet-induced obesity through enhancing leptin sensitivity and ameliorating hyperphagia in high-fat high-sucrose diet fed mice."

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Fatty Acid-Binding Proteins
3.	Dipeptidyl-Peptidase IV Inhibitors
4.	miglitol (Glyset)
5.	Cytokines
6.	Cholesterol
7.	Insulin (Novolin)
8.	Glucagon-Like Peptide 1 (GLP 1)
9.	Lipopolysaccharides
10.	Glucosidases

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Percutaneous Coronary Intervention
4.	Intraperitoneal Injections